AKUMS DRUGS & PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of AKUMS DRUGS & PHARMACEUTICALS have decreased by -1.44% YoY .
The Earnings Per Share (EPS) of AKUMS DRUGS & PHARMACEUTICALS has decreased by -24.54 % YoY. |
||
AKUMS DRUGS & PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 544222|NSE : AKUMS]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹4,118 Cr | ₹4,178 Cr | ₹3,655 Cr | ₹3,672 Cr | ₹2,723 Cr |
| Expenses | ₹3,658 Cr | ₹4,055 Cr | ₹3,361 Cr | ₹3,764 Cr | ₹2,431 Cr |
| Operating Profit (Excl OI) | ₹461 Cr | ₹123 Cr | ₹294 Cr | ₹-92 Cr | ₹291 Cr |
| Other Income | ₹56 Cr | ₹34 Cr | ₹90 Cr | ₹23 Cr | ₹21 Cr |
| Interest | ₹35 Cr | ₹51 Cr | ₹46 Cr | ₹17 Cr | ₹6.74 Cr |
| Depreciation | ₹153 Cr | ₹126 Cr | ₹113 Cr | ₹95 Cr | ₹70 Cr |
| Profit Before Tax | ₹345 Cr | ₹-45 Cr | ₹150 Cr | ₹-193 Cr | ₹172 Cr |
| Profit After Tax | ₹344 Cr | ₹0.79 Cr | ₹98 Cr | ₹-251 Cr | ₹123 Cr |
| Consolidated Net Profit | ₹338 Cr | ₹-4.04 Cr | ₹95 Cr | ₹-253 Cr | ₹123 Cr |
| Earnings Per Share (Rs) | ₹16.67 | ₹22.09 | ₹-0.28 | ₹6.63 | ₹-35.30 |
| PAT Margin (%) | 5.88 | 8.35 | 0.02 | 2.68 | -6.83 |
| ROE(%) | 8.06 | 18.30 | 0.11 | 14.61 | -33.30 |
| ROCE(%) | 14.77 | 17.83 | 0.43 | 17.59 | -18.00 |
| Total Debt/Equity(x) | 0.02 | 0.00 | 0.69 | 0.75 | 0.58 |
Key Financials |
||
| Market Cap | : | ₹ 11,983.6 Cr |
| Revenue (TTM) | : | ₹ 4,501.6 Cr |
| Net Profit(TTM) | : | ₹ 292.7 Cr |
| EPS (TTM) | : | ₹ 18.6 |
| P/E (TTM) | : | 40.9 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| AKUMS DRUGS & PHARMACEUTICALS | 1.5% | 14.6% | 59.2% |
| SUN PHARMACEUTICAL INDUSTRIES | -0% | -4.5% | 15.9% |
| DIVIS LABORATORIES | 5.9% | 16.1% | 49.6% |
| TORRENT PHARMACEUTICALS | 3% | 3% | 34% |
| CIPLA | -0.4% | -3.6% | -11.6% |
| DR REDDYS LABORATORIES | NA | 2.8% | -7.1% |
| MANKIND PHARMA | 1.9% | -6.8% | -8% |
| LUPIN | -1.3% | -11.6% | 11.7% |
| ZYDUS LIFESCIENCES | 6.2% | 5.9% | 16.4% |
AKUMS DRUGS & PHARMACEUTICALS Revenues
[BOM: 544222|NSE : AKUMS]
| Y-o-Y | -1.44 % |
| 5 Yr CAGR | 10.90 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹4,118 Cr | -1.44 | |
| Mar2025 | ₹4,178 Cr | 14.32 | |
| Mar2024 | ₹3,655 Cr | -0.46 | |
| Mar2023 | ₹3,672 Cr | 34.87 | |
| Mar2022 | ₹2,723 Cr | - | |
AKUMS DRUGS & PHARMACEUTICALS Operating Profit
[BOM: 544222|NSE : AKUMS]
| Y-o-Y | 274.53 % |
| 5 Yr CAGR | 12.15 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹461 Cr | 274.53 | |
| Mar2025 | ₹123 Cr | -58.17 | |
| Mar2024 | ₹294 Cr | Positive | |
| Mar2023 | ₹-92 Cr | Negative | |
| Mar2022 | ₹291 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 280.27 % |
| 5 Yr CAGR | 1.13 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 11.18% | 280.27 | |
| Mar2025 | 2.94% | -63.43 | |
| Mar2024 | 8.04% | Positive | |
| Mar2023 | -2.5% | Negative | |
| Mar2022 | 10.69% | - | |
AKUMS DRUGS & PHARMACEUTICALS Profit After Tax
[BOM: 544222|NSE : AKUMS]
| Y-o-Y | Positive |
| 5 Yr CAGR | 28.85 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹338 Cr | Positive | |
| Mar2025 | ₹-4.04 Cr | Negative | |
| Mar2024 | ₹95 Cr | Positive | |
| Mar2023 | ₹-253 Cr | Negative | |
| Mar2022 | ₹123 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -29.58 % |
| 5 Yr CAGR | Positive |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 5.88 % | -29.58 | |
| Mar2025 | 8.35 % | 41,650.00 | |
| Mar2024 | 0.02 % | -99.25 | |
| Mar2023 | 2.68 % | Positive | |
| Mar2022 | -6.83 % | - | |
AKUMS DRUGS & PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 544222|NSE : AKUMS]
| Y-o-Y | -24.54 % |
| 5 Yr CAGR | Positive |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹17 | -24.54 | |
| Mar2025 | ₹22 | Positive | |
| Mar2024 | ₹-0.28 | Negative | |
| Mar2023 | ₹6.63 | Positive | |
| Mar2022 | ₹-35 | - | |
AKUMS DRUGS & PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 544222|NSE : AKUMS]
| Y-o-Y | -17.16 % |
| 5 Yr CAGR | Positive |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 14.77% | -17.16 | |
| Mar2025 | 17.83% | 4,046.51 | |
| Mar2024 | 0.43% | -97.56 | |
| Mar2023 | 17.59% | Positive | |
| Mar2022 | -18% | - | |
AKUMS DRUGS & PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹761.4 |
| Current MarketCap | : | ₹ 11,983.6 Cr |
| Updated EOD on | : | Aug 27,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AKUMS DRUGS & PHARMACEUTICALS | 1.5% |
14.6% |
59.2% |
| SENSEX | -0.8% |
0.2% |
-6% |
AKUMS DRUGS & PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE HEALTHCARE | 1.2% | 2.3% | 15.3% |
| BSE 1000 | -0.3% | 1.8% | 1.7% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MIDSMALLCAP400 50:50 | 0.5% | 3.2% | NA |
| NIFTY SMALLCAP 500 | 0.5% | 4.4% | NA |
| NIFTY MICROCAP 250 | 0.4% | 5.8% | 11.3% |
| NIFTY500 LARGEMIDSMALL EQUAL-CAP WEIGHTED INDEX | 0.2% | 2.5% | 5.2% |
| NIFTY 500 EQUAL WEIGHT | 0.1% | 2.4% | 5.7% |
You may also like the below Video Courses
FAQ about AKUMS DRUGS & PHARMACEUTICALS Financials
How the annual revenues of AKUMS DRUGS & PHARMACEUTICALS have changed ?
The Revenues of AKUMS DRUGS & PHARMACEUTICALS have decreased by -1.44% YoY .
How the Earnings per Share (EPS) of AKUMS DRUGS & PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of AKUMS DRUGS & PHARMACEUTICALS has decreased by -24.54 % YoY .
Check out Intrinsic Value of Peers of AKUMS DRUGS & PHARMACEUTICALS
Compare Stock Analytics of Peers of AKUMS DRUGS & PHARMACEUTICALS
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
